Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Dorval

Showing results (31-40 of 108) with videos related to

Pageof 11
Sort By:
Cancer|July 15, 1986
Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanomaT Dorval, T Palangie, M Jouve, et al.
Cancer Detection and Prevention|January 1, 1990
Problems and prospects of new immunotherapeutic approachesW H Fridman, C Mathiot, J Michon, et al.
European Cytokine Network|June 12, 2001
Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trialG Gravis, M Mousseau, J Y Douillard, et al.
British Journal of Cancer|June 1, 1987
Similar biological effects of different low doses of interferon alpha in cancer patientsC Billard, R A Diez, D Ferbus, et al.
Presse Medicale (Paris, France : 1983)|February 21, 1987
[2 cases of pneumoblastoma with pulmonary metastases responsive to chemotherapy]P Piedbois, T Palangie, P Berzeboc, et al.
Presse Medicale (Paris, France : 1983)|April 2, 1988
[Encephalopathy caused by an ifosfamide-mesna combination]P Beuzeboc, T Dorval, E Garcia-Giralt, et al.
Bulletin Du Cancer|January 1, 1987
[Metastatic breast cancer. Modality of association of chemotherapy and hormonotherapy. Results of a controlled trial]M Jouve, T Palangie, T Dorval, et al.
Investigational New Drugs|January 1, 1987
Treatment of metastatic malignant melanoma with recombinant interferon alfa-2bT Dorval, T Palangie, M Jouve, et al.
Pathologie-Biologie|October 1, 1990
[Prognostic parameters in metastatic breast cancers]P Pouillart, J M Nadal, M Jouve, et al.
Clinical and Experimental Immunology|November 1, 1990
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gammaF Farace, C Mathiot, M Brandely, et al.
Pageof 11

Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Cancer|July 15, 1986
Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanomaT Dorval, T Palangie, M Jouve, et al.
Cancer Detection and Prevention|January 1, 1990
Problems and prospects of new immunotherapeutic approachesW H Fridman, C Mathiot, J Michon, et al.
European Cytokine Network|June 12, 2001
Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trialG Gravis, M Mousseau, J Y Douillard, et al.
British Journal of Cancer|June 1, 1987
Similar biological effects of different low doses of interferon alpha in cancer patientsC Billard, R A Diez, D Ferbus, et al.
Presse Medicale (Paris, France : 1983)|February 21, 1987
[2 cases of pneumoblastoma with pulmonary metastases responsive to chemotherapy]P Piedbois, T Palangie, P Berzeboc, et al.
Presse Medicale (Paris, France : 1983)|April 2, 1988
[Encephalopathy caused by an ifosfamide-mesna combination]P Beuzeboc, T Dorval, E Garcia-Giralt, et al.
Bulletin Du Cancer|January 1, 1987
[Metastatic breast cancer. Modality of association of chemotherapy and hormonotherapy. Results of a controlled trial]M Jouve, T Palangie, T Dorval, et al.
Investigational New Drugs|January 1, 1987
Treatment of metastatic malignant melanoma with recombinant interferon alfa-2bT Dorval, T Palangie, M Jouve, et al.
Pathologie-Biologie|October 1, 1990
[Prognostic parameters in metastatic breast cancers]P Pouillart, J M Nadal, M Jouve, et al.
Clinical and Experimental Immunology|November 1, 1990
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gammaF Farace, C Mathiot, M Brandely, et al.
Pageof 11